Tags

Type your tag names separated by a space and hit enter

Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Mult Scler Relat Disord. 2018 May; 22:139-140.MS

Abstract

The most common adverse events associated with the monoclonal antibody alemtuzumab are infusion associated reactions and secondary autoimmune disease. Respiratory complications are unusual following treatment with alemtuzumab, but can be precipitated by an infectious cause. We describe a case of a sub-acute steroid responsive non-infectious pneumonitis affecting a 51 year old woman, who presented one month after initiation of therapy for multiple sclerosis with alemtuzumab.

Links

Publisher Full Text

Authors+Show Affiliations

Whiteside D
Department of Neurology, Northwick Park Hospital, London, UK.
Barth S
Department of Respiratory Medicine, Northwick Park Hospital, London, UK.
Datta A
Department of Respiratory Medicine, Northwick Park Hospital, London, UK.
Trip SA
Department of Neurology, Northwick Park Hospital, London, UK; Queen Square MS Centre, National Hospital for Neurology & Neurosurgery, London, UK. Electronic address: anand.trip@nhs.net.

MeSH

AlemtuzumabDiagnosis, DifferentialDyspneaFemaleHumansImmunologic FactorsMiddle AgedMultiple Sclerosis, Relapsing-RemittingPneumonia

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

29684788

Citation

Whiteside, D, et al. "Pneumonitis Secondary to Alemtuzumab in a Patient With Multiple Sclerosis - a Non-infectious Cause of Breathlessness." Multiple Sclerosis and Related Disorders, vol. 22, 2018, pp. 139-140.
Whiteside D, Barth S, Datta A, et al. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness. Mult Scler Relat Disord. 2018;22:139-140.
Whiteside, D., Barth, S., Datta, A., & Trip, S. A. (2018). Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness. Multiple Sclerosis and Related Disorders, 22, 139-140. https://doi.org/10.1016/j.msard.2018.04.002
Whiteside D, et al. Pneumonitis Secondary to Alemtuzumab in a Patient With Multiple Sclerosis - a Non-infectious Cause of Breathlessness. Mult Scler Relat Disord. 2018;22:139-140. PubMed PMID: 29684788.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness. AU - Whiteside,D, AU - Barth,S, AU - Datta,A, AU - Trip,S A, Y1 - 2018/04/03/ PY - 2018/01/17/received PY - 2018/03/05/revised PY - 2018/04/02/accepted PY - 2018/4/24/pubmed PY - 2018/10/12/medline PY - 2018/4/24/entrez KW - Alemtuzumab KW - Interstitial KW - Lung diseases KW - Multiple sclerosis SP - 139 EP - 140 JF - Multiple sclerosis and related disorders JO - Mult Scler Relat Disord VL - 22 N2 - The most common adverse events associated with the monoclonal antibody alemtuzumab are infusion associated reactions and secondary autoimmune disease. Respiratory complications are unusual following treatment with alemtuzumab, but can be precipitated by an infectious cause. We describe a case of a sub-acute steroid responsive non-infectious pneumonitis affecting a 51 year old woman, who presented one month after initiation of therapy for multiple sclerosis with alemtuzumab. SN - 2211-0356 UR - https://www.unboundmedicine.com/medline/citation/29684788/Pneumonitis_secondary_to_alemtuzumab_in_a_patient_with_multiple_sclerosis___A_non_infectious_cause_of_breathlessness_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(18)30121-4 DB - PRIME DP - Unbound Medicine ER -